Nuveen Asset Management LLC Cuts Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Nuveen Asset Management LLC lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 30.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 4,552,317 shares of the biotechnology company's stock after selling 2,025,560 shares during the quarter. Nuveen Asset Management LLC owned 1.93% of ADMA Biologics worth $78,072,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of ADMA Biologics in the 4th quarter valued at $19,076,000. Allspring Global Investments Holdings LLC grew its holdings in shares of ADMA Biologics by 1,144.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock worth $51,016,000 after purchasing an additional 2,613,482 shares during the period. Veracity Capital LLC boosted its holdings in ADMA Biologics by 117.0% during the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after acquiring an additional 25,030 shares during the period. Nkcfo LLC purchased a new position in shares of ADMA Biologics in the 4th quarter valued at about $325,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of ADMA Biologics by 272.5% in the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after buying an additional 561,310 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ADMA shares. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th. StockNews.com cut ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Finally, Raymond James upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock traded down $0.32 on Wednesday, hitting $20.12. The stock had a trading volume of 2,405,413 shares, compared to its average volume of 3,701,458. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of 71.86 and a beta of 0.57. ADMA Biologics, Inc. has a twelve month low of $9.31 and a twelve month high of $25.67. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business's 50 day moving average is $20.61 and its two-hundred day moving average is $18.90.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business's revenue was up 40.2% on a year-over-year basis. During the same period last year, the business posted $0.08 earnings per share. Analysts forecast that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.